We’re on a mission to fulfill the promise of genetic medicine for all patients
At Addition, we are advancing a pipeline of therapeutics to deliver functional cures for patients with severe lifelong diseases in large and rare populations.
At the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting, which took place in Boston, MA, May 11-15, 2006, we presented preclinical proof-of-concept data for our PRINT™ platform and multiple disease areas, including obesity, Fabry, HIV and ocular disease.
About Us
Today, the field of genetic medicine is composed of two primary modalities: RNA therapeutics and gene therapies. Both modalities have delivered important advances for patients, but each is limited to distinct applications.
At Addition, we are combining the efficacy, safety and scalability profile of RNA therapeutics with the multi-year durability of gene therapies.
Our best of both modalities approach — enabled by our PRINT technology — has the potential to further unlock the potential of genetic medicines and deliver functional cures for patients with severe lifelong diseases.
We’re focused initially on rare patient populations with severe, life-threatening unmet needs, with the goal of ultimately also addressing larger, related patient populations.
Promise
We’re committed to transformational impact for patients.
Latest news
Addition Therapeutics Presents Preclinical Proof-of-Concept Data at American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting
Platform non-human primate (NHP) data demonstrate stable, durable protein expression enabled by all-RNA, LNP-based PRINT technology. Preclinical proof-of-concept rodent data being presented in multiple disease areas, including obesity, Fabry, HIV and ocular disease. Breadth of data demonstrate PRINT’s potential to...
Addition Therapeutics Announces Multiple Oral and Poster Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting
“Best of both modalities” approach combines the efficacy, safety and scalability of RNA therapeutics with the multi-year durability of gene therapies. Portfolio prioritizes rare, severe, lifelong non-genetic and genetic diseases first, with the intent to expand into larger, related patient...
Addition Therapeutics Announces $100 Million in Funding and Significant Progress Advancing Mission to Fulfill Promise of Genomic Medicine for Chronic and Rare Diseases
All-RNA, non-viral, LNP-based PRINT™ platform is designed to develop safer, durable, one-time therapies for a broad range of unmet needs. Addition is advancing a robust pipeline of PRINTed therapeutics for chronic and rare indications, with initial disease-related non-human primate (NHP)...
